FIBROLINE
6.2.2020 15:02:13 CET | Business Wire | Press release
The french engineering company FIBROLINE has developed and patented a portfolio of powder impregnation technologies for all types of porous materials. These technologies, based on the application of alternating electric fields, allow the homogeneous distribution of materials in powder form into textiles, non-wovens, foams, papers, enabling the functionalization of these materials in a dry process. It allows the creation of new products for non-soluble actives, and/or the substitution of conventional liquid solutions, reducing their environmental and energy impact. Following industrial successes in technical textiles, composite materials and hygiene, FIBROLINE has patented an adaptation of its solutions to the medical and biomedical sector, allowing contact impregnation: the "S-Preg" technology.
This technology opens up the possibility of use in environments requiring a high level of cleanliness, thus avoiding any cross-contamination between active ingredients. Deposits can be made in very small quantities, or the powder can be localized in a way that is impossible to achieve with traditional sprinkling methods. Although potentially suitable for many markets, the first applications are in the medical sector, with two major licenses signed in 2019.
GATT Technologies BV (GATT-Netherlands) & FIBROLINE have entered into an exclusive license agreement for hemostatic patches (GATT-Patch). Achieving hemostasis (bleeding control) is a critical focus of clinicians working in the surgical setting. The current set of available hemostatic products do not offer adequate solutions yet for controlling heavier bleedings, especially in case patients receive anticoagulants.
The S-Preg FIBROLINE technology is very efficient to distribute active substances like NHS-POx polymers into biocompatible porous structures such as nonwovens or foams. GATT & FIBROLINE following a successful R&D program, developed innovative dry impregnated hemostatic patches combining high performance and fast hemostasis into a strong adhesive/sealing formulation on surrounding wet tissue.
Smith & Nephew , leading portfolio medical technology company, operating in over 100 countries, entered into an exclusive license agreement together with FIBROLINE .
FIBROLINE has an innovation centre near Lyon with laboratory and semi-industrial facilities allowing the development of products and the accompaniment of its customers from feasibility studies until the market industrialization step.The company's business model is the transfer of technologies through licensing agreements. Fibroline will open an R&D centre in Charlotte (USA) in May 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005007/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom